Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22289099 | 1.00 | PGD (0.33) | PGDLMNASMN1; SMN2 | |
| SCHEMBL3710989 | 1.00 | PGD (0.33) | PGDLMNASMN1; SMN2 | |
| SCHEMBL2636857 | 0.87 | SMN1; SMN2 (0.35) | PGDLMNASMN1; SMN2 | |
| SCHEMBL16291264 | 0.83 | — | — | |
| SCHEMBL16291265 | 0.83 | — | — | |
| SCHEMBL9582436 | 0.83 | LMNA (0.31) | PGDLMNASMN1; SMN2 | |
| SCHEMBL5451481 | 0.82 | LMNA (0.33) | PGDLMNASMN1; SMN2 | |
| SCHEMBL9274693 | 0.82 | PRKCA (0.33) | PGDLMNASMN1; SMN2 | |
| SCHEMBL22288952 | 0.82 | PRKCA (0.33) | PGDLMNASMN1; SMN2 | |
| SCHEMBL2386147 | 0.82 | LMNA (0.33) | PGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917924-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | Femtogenix Limited (GB) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020157491-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| US-9359395-B2 | Prodrugs of steroidal CYP17 inhibitors/antiandrogens | TOKAI PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| EP-3023433-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | Tokai Pharmaceuticals, Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2393827-B1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS INC (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20140371181-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20110312916-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2393827-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | Tokai Pharmaceuticals, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010091306-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371181-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | CYP21A2, CYP17A1, CYP19A1 | PGD 243/4885LMNA 4515/4885SMN1; SMN2 4572/4885 |
| US-20110312916-A1 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | CYP21A2, CYP17A1, CYP19A1 | PGD 239/4885LMNA 4359/4885SMN1; SMN2 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.